Technical Analysis for IPA - ImmunoPrecise Antibodies Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 10.55% | |
| Oversold Stochastic | Weakness | 10.55% | |
| Narrow Range Bar | Range Contraction | 8.20% | |
| Stochastic Reached Oversold | Weakness | 8.20% | |
| Wide Bands | Range Expansion | 8.20% | |
| Gapped Up | Strength | 8.20% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
| Rose Above 10 DMA | about 17 hours ago |
| Up 5% | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 03/14/2024
ImmunoPrecise Antibodies Ltd. Description
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Immunology Antibodies Monoclonal Antibody Antibody Cloning Screening
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.22 |
| 52 Week Low | 0.95 |
| Average Volume | 716,151 |
| 200-Day Moving Average | 1.74 |
| 50-Day Moving Average | 1.54 |
| 20-Day Moving Average | 1.34 |
| 10-Day Moving Average | 1.25 |
| Average True Range | 0.10 |
| RSI (14) | 44.75 |
| ADX | 17.88 |
| +DI | 17.01 |
| -DI | 22.08 |
| Chandelier Exit (Long, 3 ATRs) | 1.33 |
| Chandelier Exit (Short, 3 ATRs) | 1.48 |
| Upper Bollinger Bands | 1.53 |
| Lower Bollinger Band | 1.14 |
| Percent B (%b) | 0.45 |
| BandWidth | 29.23 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.0055 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.52 | ||||
| Resistance 3 (R3) | 1.50 | 1.41 | 1.48 | ||
| Resistance 2 (R2) | 1.41 | 1.36 | 1.42 | 1.47 | |
| Resistance 1 (R1) | 1.37 | 1.33 | 1.39 | 1.39 | 1.46 |
| Pivot Point | 1.28 | 1.28 | 1.30 | 1.29 | 1.28 |
| Support 1 (S1) | 1.24 | 1.23 | 1.26 | 1.26 | 1.18 |
| Support 2 (S2) | 1.15 | 1.20 | 1.16 | 1.17 | |
| Support 3 (S3) | 1.11 | 1.15 | 1.16 | ||
| Support 4 (S4) | 1.13 |
